Tenon Medical (TNON) Expected to Post Earnings on Thursday

Tenon Medical (NASDAQ:TNON) is projected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($8.40) per share and revenue of $1.54 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Tenon Medical (NASDAQ:TNON) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($10.85) EPS for the quarter, missing the consensus estimate of ($10.68) by ($0.17). Tenon Medical had a negative net margin of 270.09% and a negative return on equity of 907.60%. The company had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.30 million.

Tenon Medical Trading Up 1.5%

TNON opened at $6.14 on Wednesday. The business has a 50 day moving average of $11.92 and a 200-day moving average of $21.82. The stock has a market capitalization of $2.09 million, a price-to-earnings ratio of -0.14 and a beta of 1.39. Tenon Medical has a 1-year low of $4.38 and a 1-year high of $60.90.

Institutional Trading of Tenon Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. DRW Securities LLC bought a new stake in shares of Tenon Medical in the 4th quarter valued at approximately $98,000. Geode Capital Management LLC increased its holdings in Tenon Medical by 34.6% during the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock valued at $63,000 after purchasing an additional 17,137 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Tenon Medical during the first quarter worth $29,000. Institutional investors own 22.74% of the company’s stock.

Analysts Set New Price Targets

TNON has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Tenon Medical in a research report on Friday, July 17th. Alliance Global Partners reiterated a “buy” rating on shares of Tenon Medical in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.